Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2500 - A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548


09 Oct 2016


Poster display


Michael Weller


Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367


M. Weller1, G. Vlahovic2, M. Khasraw3, A.A. Brandes4, R. Zwirtes5, K. Tatsuoka6, A.F. Carpentier7, D.A. Reardon8, M. van den Bent9

Author affiliations

  • 1 Department Of Neurology, University Hospital Zurich, 8091 - Zurich/CH
  • 2 Brain Tumor Immunotherapy Clinical Research, Duke University Medical Center, Durham/US
  • 3 Sydney Medical School And Medical Oncologist, University of Sydney, Sydney/AU
  • 4 Medical Oncology Dept, AUSL BOLOGNA-Italy, 40139 - Bologna/IT
  • 5 Medical Monitor, Bristol-Myers Squibb, 08540 - Princeton/US
  • 6 Biostatistics, Bristol-Myers Squibb, 08540 - Princeton/US
  • 7 Assistance Publique-hôpitaux De Paris, Service De Neurologie, Hôpital Avicenne, Bobigny/FR
  • 8 Center For Neuro-oncology, Dana-Farber Cancer Institute, Boston/US
  • 9 Neuro-oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA - Rotterdam/NL


Abstract 2500


GBM, the most common adult primary brain tumor, has an aggressive clinical course and a poor prognosis. Approximately 40% of pts with GBM have tumors with a methylated MGMT gene promoter, which is associated with DNA repair. In these pts, TMZ may induce DNA damage and cell death due to silencing of the MGMT promoter, a mechanism potentially augmented by combination with checkpoint inhibitors. Nivolumab, a fully human IgG4 monoclonal antibody to the programmed death-1 receptor, has demonstrated overall survival (OS) benefit in the treatment of metastatic melanoma, non-small cell lung cancer, and advanced renal cell carcinoma. CheckMate-548 (NCT02667587) is a phase 2, randomized, single-blind study evaluating the efficacy and safety of TMZ/RT —> TMZ with nivolumab or PBO in pts with newly diagnosed MGMT-methylated GBM. In a companion phase 3 trial (CheckMate-498; NCT02617589), eligible pts with MGMT-unmethylated tumors (N = 550) will be randomized to receive nivolumab + RT followed by nivolumab, or TMZ/RT —> TMZ, with OS as the primary endpoint.

Trial design

Eligibility criteria include newly diagnosed, histologically confirmed supratentorial GBM in pts aged ≥18 years with Karnofsky performance status ≥70, and a tumor test result that shows a MGMT methylated, partially methylated, or indeterminate methylation type. Pts previously treated for GBM other than by resection and those with recurrent or secondary GBM are ineligible. Approximately 320 pts, stratified by partial or complete resection, will be randomized 1:1 to receive TMZ/RT —> TMZ in combination with nivolumab or PBO. Treatment will continue until disease progression or unacceptable toxicity. The primary objective is OS in pts treated with TMZ/RT —> TMZ and nivolumab versus TMZ/RT —> TMZ and PBO; the secondary objective is progression-free survival. Select exploratory objectives include safety, biomarker analyses, and neurocognitive outcomes. In the follow-up period, safety and tolerability, tumor progression, and survival will be evaluated.

Clinical trial identification

Legal entity responsible for the study

Bristol-Myers Squibb


Bristol-Myers Squibb


M. Weller: Has received research funding and/or honoraria from Celldex, ICT, Isarna, Magforce, MSD, Merck SG, Novocure, Northwestern Bio, Pfizer, Roche, Teva, Acceleron Pharma, Bayer. G. Vlahovic: Received research funding, honoraria, provided consulting or advisory services, or had travel, accommodations, or other expenses paid or reimbursed by Genentech, Pfizer, Hospira, or Bristol-Meyers Squibb. A.A. Brandes: Has had travel, accommodations, or other expenses paid or reimbursed by Roche

R. Zwirtes: Is an employee of Bristol-Myers Squibb who sponsored this study. K. Tatsuoka: Is an employee of Bristol-Myers Squibb who sponsored this study, and has patents, royalties, or other intellectual property interests related to GlaxoSmithKline. A.F. Carpentier: Has provided consulting services for Bristol-Myers Squibb. D.A. Reardon: Received research funding, honoraria, or provided consulting for Cavion, Genentech/Roche, Merck, Momenta, Novartis, Novocure, Regeron, Stemline Ther, BMS, Inovio, Juno Ther, Celldex, Oxigene, Celldex, Incyte, Midatech, Monteris Medical, Abbvie. M. van den Bent: Provided consulting or advisory services, or received research funding from Cavion, Roche, Merck, Serono, Actelion, Abbvie, Celldex, Amgen, Blue Earth Diagnostics, Novocure, Novartis, and Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings